BIOMAT Database Logo BIOMAT Database Logo

Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. 2014

Christopher G C A Jackson, and Katrina Sharples, and Paul I Thompson, and Anne O'Donnell, and Bridget Anne Robinson, and David J Perez, and Jacqui Adams, and Richard Isaacs, and Sanjeev Deva, and Victoria A Hinder, and Michael P Findlay

BACKGROUND Dose intense chemotherapy may improve efficacy with acceptable toxicity. A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer (mCRC). METHODS 49 patients with previously untreated mCRC were recruited. Nineteen received capecitabine (1750 mg/m(2) oral BD days 1-7)oxaliplatin (85 mg/m(2)i.v. day 1) and bevacizumab (5 mg/kg i.v. day 1) using a 14-day cycle (C1750). Following toxicity concerns capecitabine was reduced to 1500 mg/m2oral BD (C1500) and 30 further patients recruited. RESULTS Over 80% of patients received at least 75% of planned chemotherapy doses over the first two cycles. At C1750 Grade 3 or higher toxicity occurred in 74% (95% CI 49% to 91%) and on C1500 in 70% (95% CI 51% to 85%). The median progression-free survival was 6.9 months (95% CI 4.7 to 8.7) for C1750 dose and 8.9 months (95% CI 4.1 to 12.4) for C1500. 3 treatment-related deaths occurred. CONCLUSIONS Dose intense capecitabine and oxaliplatin with bevacizumab does not show additional efficacy and has potentially significant toxicity. Its use outside of clinical trials is not recommended. BACKGROUND ISRCTN41540878.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009944 Organoplatinum Compounds Organic compounds which contain platinum as an integral part of the molecule. Compounds, Organoplatinum
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Christopher G C A Jackson, and Katrina Sharples, and Paul I Thompson, and Anne O'Donnell, and Bridget Anne Robinson, and David J Perez, and Jacqui Adams, and Richard Isaacs, and Sanjeev Deva, and Victoria A Hinder, and Michael P Findlay
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.
September 2011, Clinical colorectal cancer,
Christopher G C A Jackson, and Katrina Sharples, and Paul I Thompson, and Anne O'Donnell, and Bridget Anne Robinson, and David J Perez, and Jacqui Adams, and Richard Isaacs, and Sanjeev Deva, and Victoria A Hinder, and Michael P Findlay
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
January 2013, Oncology research,
Christopher G C A Jackson, and Katrina Sharples, and Paul I Thompson, and Anne O'Donnell, and Bridget Anne Robinson, and David J Perez, and Jacqui Adams, and Richard Isaacs, and Sanjeev Deva, and Victoria A Hinder, and Michael P Findlay
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer.
September 2003, Annals of oncology : official journal of the European Society for Medical Oncology,
Christopher G C A Jackson, and Katrina Sharples, and Paul I Thompson, and Anne O'Donnell, and Bridget Anne Robinson, and David J Perez, and Jacqui Adams, and Richard Isaacs, and Sanjeev Deva, and Victoria A Hinder, and Michael P Findlay
Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis.
July 2010, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland,
Christopher G C A Jackson, and Katrina Sharples, and Paul I Thompson, and Anne O'Donnell, and Bridget Anne Robinson, and David J Perez, and Jacqui Adams, and Richard Isaacs, and Sanjeev Deva, and Victoria A Hinder, and Michael P Findlay
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
March 2015, Cancer chemotherapy and pharmacology,
Christopher G C A Jackson, and Katrina Sharples, and Paul I Thompson, and Anne O'Donnell, and Bridget Anne Robinson, and David J Perez, and Jacqui Adams, and Richard Isaacs, and Sanjeev Deva, and Victoria A Hinder, and Michael P Findlay
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
October 2010, Japanese journal of clinical oncology,
Christopher G C A Jackson, and Katrina Sharples, and Paul I Thompson, and Anne O'Donnell, and Bridget Anne Robinson, and David J Perez, and Jacqui Adams, and Richard Isaacs, and Sanjeev Deva, and Victoria A Hinder, and Michael P Findlay
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
January 2011, Anticancer research,
Christopher G C A Jackson, and Katrina Sharples, and Paul I Thompson, and Anne O'Donnell, and Bridget Anne Robinson, and David J Perez, and Jacqui Adams, and Richard Isaacs, and Sanjeev Deva, and Victoria A Hinder, and Michael P Findlay
Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
October 2015, Cancer medicine,
Christopher G C A Jackson, and Katrina Sharples, and Paul I Thompson, and Anne O'Donnell, and Bridget Anne Robinson, and David J Perez, and Jacqui Adams, and Richard Isaacs, and Sanjeev Deva, and Victoria A Hinder, and Michael P Findlay
Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
January 2009, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
Christopher G C A Jackson, and Katrina Sharples, and Paul I Thompson, and Anne O'Donnell, and Bridget Anne Robinson, and David J Perez, and Jacqui Adams, and Richard Isaacs, and Sanjeev Deva, and Victoria A Hinder, and Michael P Findlay
Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial.
August 2023, EClinicalMedicine,
Copied contents to your clipboard!